SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Granules India informs about press release

17 Dec 2024 Evaluate
Granules India has informed that it enclosed press release ‘Granules India Limited Announces FDA Approval for ADHD Treatment, Addressing Drug Shortages in the US’.

The above information is a part of company’s filings submitted to BSE.

Granules India Share Price

677.25 9.10 (1.36%)
22-Apr-2026 14:19 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1664.65
Dr. Reddys Lab 1218.90
Cipla 1235.90
Zydus Lifesciences 931.00
Lupin 2301.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×